Envestnet Asset Management Inc. Sells 1,861 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Envestnet Asset Management Inc. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 101,561 shares of the biopharmaceutical company’s stock after selling 1,861 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $57,105,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Salomon & Ludwin LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $31,000. Traub Capital Management LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $38,000. Berbice Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 35 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.7%

NASDAQ REGN opened at $780.28 on Tuesday. The firm has a market capitalization of $82.01 billion, a PE ratio of 18.77, a P/E/G ratio of 2.11 and a beta of 0.40. The stock’s 50 day moving average is $757.89 and its 200 day moving average is $660.34. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm posted $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.47%.

Analysts Set New Price Targets

REGN has been the topic of several recent analyst reports. Truist Financial cut their target price on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Sunday. HSBC initiated coverage on Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Finally, UBS Group boosted their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $793.81.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.